<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167491</url>
  </required_header>
  <id_info>
    <org_study_id>P081238</org_study_id>
    <nct_id>NCT01167491</nct_id>
  </id_info>
  <brief_title>Study of One Protein Implicated in Wegener Disease</brief_title>
  <acronym>DAP12WEGENER</acronym>
  <official_title>Activating Receptors and DAP12 Protein in Wegener's Granulomatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators recently showed an abnormal expansion of NK-like CD4+ T cells in Wegener's
      granulomatosis (WG), mainly in the diffuse vasculitis presentation. These cells expressed an
      assortment of activating NK cell receptors and their signaling partners, in particular DAP12.
      The investigators hypothesize that DAP12, or a downstream signaling target of DAP12, is the
      missing link between the different cell components involved in WG (neutrophils, macrophages,
      CD4 T cells).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will test our hypothesis of &quot;DAP-12 gain-of-function&quot; by quantitative (mRNA
      and protein) and qualitative (DNA, signaling and cellular activation) analysis of the DAP12
      signaling pathway in WG patients with localized (group 1; n=30) or diffuse WG (group 2; n=30)
      by comparison with patients with micro polyangitis (group 3; n=30), or with sarcoidosis (
      group 4; n=30), and healthy blood donors (group 5; n=30). Blood samples will be collected
      during a routine medical visit. These results may help to design future therapeutic
      strategies based on modulation of specific intra-cellular pathways involved in the disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>level of mRNA expression of DAP12</measure>
    <time_frame>less than 24 hours</time_frame>
    <description>Measure:level of mRNA expression of DAP12 by RT-PCR in CD4+T cells, macrophages and neutrophils</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>level of expression of DAP 12 downstream signalling proteins</measure>
    <time_frame>Less than 24 hours</time_frame>
    <description>Measure: level of expression of DAP 12 downstream signalling proteins in CD4+ T cells, macrophages and neutrophils</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Wegener's Granulomatosis</condition>
  <arm_group>
    <arm_group_label>Disease group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Physiopathology</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Physiopathology Endpoint Classification</intervention_name>
    <description>Blood samples will be collected during a routine medical visit.</description>
    <arm_group_label>Disease group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1: WG, with granulomatous lesions limited to upper airway or lungs and no
             evidence of generalized vasculitis ,± biopsy, ± anti-PR3 ANCA

          -  Group 2: WG with granulomatous lesions plus vasculitis expression (renal,
             neurological, skin, gut or heart involvement), ± biopsy, ± anti-PR3 ANCA

          -  Group 3: Necrotizing vasculitis with no granulomatous lesions, ± PAUCI immune
             glomerulonephritis, ± anti-MPO ANCA

          -  Group 4: clinical presentation compatible with sarcoidosis, ± biopsy, ± ECA elevated ±
             tuberculin anergy

        Exclusion Criteria:

          -  &lt;18 years

          -  Pregnancy or breastfeeding

          -  Absence of signed informed consent

          -  No affiliation to insurance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathilde De Menthon,, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medecine Interne Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wegener</keyword>
  <keyword>CD4+ T cells</keyword>
  <keyword>DAP12</keyword>
  <keyword>NKG2D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

